Moti L. Kashyap - Concepedia

Author

Moti L. Kashyap

Also Known As

M KASHYAP, M Kashyap, M L Kashyap, M. Kashyap, M. L. KASHYAP, M. L. Kashyap, M.L Kashyap, M.L. Kashyap, MOTI L KASHYAP, Moti Kashyap

225

Publications

14K

Citations

H-Index

142

Concepts

All Affiliations

University of California, Irvine VA Long Beach Healthcare System University of Cincinnati Medical Center Long Beach Medical Center University of Cincinnati

About

Moti L. Kashyap is an author at University of California, Irvine specializing in medicine, atherosclerosis, and physiology.

Top Concepts

#	Concept	H-Index	Publications	Citations
1	Medicine	41	73	8.9K
2	Health Sciences	20	22	2K
3	Public Health	11	12	3.5K
4	Natural Sciences	6	6	339
5	Engineering	1	1	12

Moti L. Kashyap

105

Publications

11.8K

Citations

H-Index

Page 1

	Year	Citations
Dulaglutide and cardiovascular outcomes in type 2 diabetes (REWIND): a double-blind, randomised placebo-controlled trial Hertzel C. Gerstein, Helen M. Colhoun, Gilles R. Dagenais, The Lancet Metabolic SyndromeDiabetes ManagementCardiovascular DiseaseHealth PolicyCardiovascular Outcomes	2019	2.8K
Relation of Gemfibrozil Treatment and Lipid Levels With Major Coronary Events Sander J. Robins, Dorothea Collins, Janet Wittes, JAMA	2001	922
Dulaglutide and renal outcomes in type 2 diabetes: an exploratory analysis of the REWIND randomised, placebo-controlled trial Hertzel C. Gerstein, Helen M. Colhoun, Gilles R. Dagenais, The Lancet Metabolic SyndromeDiabetes ManagementUrologyChronic Kidney DiseaseDiabetes	2019	600
Interchange of Apolipoproteins between Chylomicrons and High Density Lipoproteins during Alimentary Lipemia in Man Richard J. Havel, John P. Kane, Moti L. Kashyap Journal of Clinical Investigation ObesityMetabolic SyndromeNutritionHigh DensityBody Composition	1973	528
Relationship of Apolipoproteins A-1 and B, and Lipoprotein(a) to Cardiovascular Outcomes John J. Albers, April Slee, Kevin D. O’Brien, Journal of the American College of Cardiology Metabolic SyndromeVascular DiseaseApolipoproteins A-1Cardiovascular EpidemiologyCardiovascular Disease	2013	309
Equivalent efficacy of a time-release form of niacin (Niaspan) given once-a-night versus plain niacin in the management of hyperlipidemia Robert H. Knopp, Michael Davidson, Anne C. Goldberg, Metabolism PharmacologyPharmacotherapyTime-release FormMedicineEquivalent Efficacy	1998	238
Distribution of lipids in 8,500 men with coronary artery disease Hanna E. Bloomfield, Sander J. Robins, Dorothea Collins, The American Journal of Cardiology	1995	238
Long-term safety and efficacy of a once-daily niacin/lovastatin formulation for patients with dyslipidemia**A complete list of participants in the Research Group and Publication Committee appears in the Appendix. Moti L. Kashyap, Mark E. McGovern, Kathleen Berra, The American Journal of Cardiology Drug SafetyCardiovascular DiseaseMedicinePublication CommitteePharmacotherapy	2002	234
Niacin inhibits vascular oxidative stress, redox-sensitive genes, and monocyte adhesion to human aortic endothelial cells Shobha H. Ganji, Shucun Qin, Linhua Zhang, Atherosclerosis InflammationVascular Oxidative StressCardiovascular DiseaseMedicineVascular Adaptation	2008	233
Niacin noncompetitively inhibits DGAT2 but not DGAT1 activity in HepG2 cells Shobha H. Ganji, Daming Zhu, Yiding Xing, Journal of Lipid Research Lipid AnalysisImmunologyMolecular PharmacologyDgat1 ActivityLipid Chemistry	2004	226

Page 1